Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age

Journal of Endocrinological Investigation

Volumn 28, Issue 7, 2005, Pages 440-448

  Colao, A ^a   Spiezia, S ^b   Di Somma, C ^a   Pivonello, R ^a   Marzullo, P ^a   Rota, F ^a   Musella, T ^a   Auriemma, R S ^a   De Martino, M C ^a   Lombardi, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b S Maria degli Incurabili Hospital of Naples   (Italy)

Author keywords

Atherosclerosis; Common carotids; IGF 1; Intima media thickness; Lipid profile

Indexed keywords

ARGININE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; AGE; AGED; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BODY MASS; CARDIOVASCULAR RISK; COMMON CAROTID ARTERY; CONTROLLED STUDY; FEMALE; HOMEOSTASIS; HUMAN; MALE; PARAMETER; PATHOGENESIS; PROTEIN SECRETION; TUNICA MEDIA; ADOLESCENT; ARTERIOSCLEROSIS; BLOOD; CAROTID ARTERY; HISTOLOGY; INTIMA; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTION AND FORECASTING; REFERENCE VALUE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CAROTID ARTERIES; HOMEOSTASIS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LIPIDS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; TUNICA INTIMA;

EID: 24344440463     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03347225     Document Type: Article

References (41)

1. Bayes-Genis A, Conover CA, Schwartz RS. The insulin-like growth factor axis. A review of atherosclerosis and restenosis. Circ Res 2000, 86: 125-30.
2. Delafontaine P. Insulin-like growth factor 1 and its binding proteins in the cardiovascular system. Cardiovasc Res 1995, 30: 825-34.
3. Fernas GAA, Morani AS, Anggard EE. The insulin-like growth factors: their putative role in atherogenesis. Artery 1991, 18: 197-225.
4. Markussis V, Beshyah SA, Fisher C, Sharp P, Nicholaides AN, Johnston D. Detection of premature atherosclerosis by high resolution ultrasonography in symptom free hypopituitary adults. Lancet 1992, 340: 1188-92.
5. Capaldo B, Patti L, Oliviero U, et al. Increased arterial intima-media thickness in childhood-onset growth hormone deficiency. J Clin Endocrinol Metab 1997, 82: 1378-81.
6. Borson-Chazot F, Serusclat A, Kalfallah Y, et al. Decrease in carotid intima-media thickness after 1 year growth hormone (GH) treatment in adults with GH deficiency. J Clin Endocrinol Metab 1999, 84: 1329-33.
7. Pfeifer M, Verhovec R, Zizek B, Prezelj J, Poredos P, Clayton RN. Growth hormone treatment (GH) reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab 1999, 84: 453-7.
8. Murata M, Kaji H, Mizuno I, et al. A study of carotid intima-media thickness in GH-deficient Japanese adults during onset among adults and children. Eur J Endocrinol 2003, 148: 333-8.
9. Leonsson M, Hulthe J, Oscarsson J, et al. Intima-media thickness in cardiovascularly asymptomatic hypopituitary adults with growth hormone deficiency: relation to body mass index, gender, and other cardiovascular risk factors. Clin Endocrinol (Oxf) 2002, 57: 751-9.
10. Colao A, Di Somma C, Filippella M, et al. Insulin-like growth factor-1 deficiency determines increased intima-media thickness at common carotid arteries in adult patients with growth hormone deficiency. Clin Endocrinol (Oxf) 2004, 61: 360-6.
11. Colao A, Spiezia S, Cerbone G, et al. Increased arterial intima-media thickness by B-M mode echodoppler ultra-sonography in acromegaly. Clin Endocrinol (Oxf) 2001, 54: 515-24.
12. Kasayama S, Otsuki M, Takagi M, et al. Characterization of premature atherosclerosis of carotid arteries in acromegalic patients. Clin Endocrinol (Oxf) 2001, 54: 791-6.
13. Colao A, Marzullo P, Lombardi G, the Multicenter Italian Study Group on Lanreotide. Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol 2002, 146: 303-9.
14. Colao A, Spinelli L, Cuocolo A, et al. Cardiovascular consequences of early-onset growth hormone excess. J Clin Endocrinol Metab 2002, 87: 3097-104.
15. Maison P, Demolis P, Young J, Schaison G, Giudicelli JF, Chanson P. Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. Clin Endocrinol (Oxf) 2000, 53: 445-51.
16. Brevetti G, Marzullo P, Silvestro A, et al. Early vascular alterations in acromegaly. J Clin Endocrinol Metab 2002, 87: 3174-9.
17. Evans LM, Davies JS, Anderson RA, et al. The effect of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiency. Eur J Endocrinol 2000, 142: 254-62.
18. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor 1 is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002, 106: 939-44.
19. Vasan RS, Sullivan LM, D'Agostino RB, et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann Intern Med 2003, 139: 642-8.
20. Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor 1 (IGF-1) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab 2004, 89: 114-20.
21. Aimaretti G, Cornell G, Razzore P, et al. Comparison between insulin-induced hypoglycemic and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults. J Clin Endocrinol Metab 1998, 83: 1615-8.
22. Castelli WP. Lipid, risk factors and ischaemic heart disease. Atherosclerosis 1996, 124(Suppl): S1-9.
23. Hypertension control. Report of a WHO expert committee. WHO Tech Rep Ser 1996, 862: 1-83.
24. Consensus Conference: treatment of hypertriglyceridemia. JAMA 1984, 251: 1196-200.
25. The Expert Panel: Report of the National Cholesterol Education Program expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med 1988, 148: 36-9.
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412-9.
27. Belcaro G, Laurora G, Cesarone MR. Noninvasive ultrasonic biopsy: evaluation of early arteriosclerotic lesions progression in normal asymptomatic, hyperlipidemic and diabetic subjects. Angiology 1993, 44: 93-9.
28. Oscarsson J, Johannsson G, Johansson JO, Lundberg PA, Lindstedt G, Bengtsson BA. Diurnal variation in serum insulin-like growth factor (IGF)-1 and IGF binding protein-3 concentrations during daily subcutaneous injections of recombinant human growth hormone in GH-deficient adults. Clin Endocrinol (Oxf) 1997, 46: 63-8.
29. Fischer F, Schulte H, Mohan S, et al. Associations of insulin-like growth factors, insulin-like growth factor binding proteins and acid-labile subunit with coronary heart disease. Clin Endocrinol (Oxf) 2004, 61: 595-602.
30. Ruotolo G, Bavenholm P, Brismar K, et al. Serum insulin-like growth factor-1 level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment. J Am Coll Cardiol 2000, 35: 647-54.
31. Spallarossa P, Brunelli C, Minuto F, et al. Insulin-like growth factor 1 and angiographically documented coronary artery disease. Am J Cardiol 1996, 336: 200-2.
32. Janssen JAMJL, Stolk RP, Pols HAP, Grobee DE, Lamberts SWJ. Serum total IGF-1, free IGF-1, and IGFBP-1 levels in an elderly population: relation to cardiovascular risk factors and disease. Arterioscl Thromb Vasc Biol 1998, 18: 277-82.
33. Cleland SJ, Petrie JR, Ueda S, Elliott HL, Connell JMC. Mechanisms and pathophysiological significance of insulin's vascular action. Curr Opin Endocrinol Diab 1998, 5: 217-22.
34. Attia N, Tamborlane WV, Heptulla R, et al. The metabolic syndrome and insulin-like growth factor 1 regulation in adolescent obesity. J Clin Endocrinol Metab 1998, 83: 1467-71.
35. Ghigo E, Goffi S, Nicolosi M, et al. 1990 Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man. J Clin Endocrinol Metab 71: 1481-5.
36. Böger RH, Skamira C, Bode-Böger SM, Brabant C, von Zur Muhlen A, Frolich JC. Nitric oxide mediates the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. J Clin Invest 1996, 98: 2706-13.
37. Rosen T, Bengtsson B-A. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990, 336: 285-8.
38. Bülow B, Hagmar L, Mikoczy Z, Nordstroem CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997, 46: 75-81.
39. Bates AS, van't Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996, 81: 1169-72.
40. Tomlinson JW, Holden N, Hills R, et al. Premature mortality in 1014 patients with hypopituitarism. Lancet 2001, 357: 425-31.
41. Frystyk J, Ledet T, Moller N, Flyvbjerg A, Orskov H. Cardiovascular disease and insulin-like growth factor 1. Circulation 2002, 106: 893-5.